Circuit Rankings

Migration, Crosslink

📖

Circuit Rankings

active

wiki page Created: 2026-04-02T07:19:34 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-circuits-rankings

📖 Wiki Page

circuit2783 wordssynced 2026-04-02

Circuit Rankings

Overview

Circuit Rankings prioritizes neural circuits for therapeutic intervention and research focus in neurodegenerative disease. The ranking system integrates multiple factors including therapeutic accessibility, clinical impact, mechanistic understanding, and current research activity to guide both scientific investigation and clinical development priorities[@deveney2022].

Neural circuits represent the fundamental organizational units of brain function, and their targeted dysfunction underlies the characteristic symptom profiles of different neurodegenerative diseases. Understanding which circuits offer the greatest therapeutic potential—and which are most actively researched—helps prioritize resource allocation for drug discovery, device development, and clinical trial design.

This page ranks circuits across three dimensions: therapeutic targeting potential (how accessible and impactful intervention could be), research activity (publication volume and trial intensity), and disease burden (how directly each circuit relates to specific neurodegenerative conditions).

Rankings by Therapeutic Targeting

Neural circuits are prioritized for therapeutic intervention based on their accessibility to various modulation techniques, the feasibility of achieving clinically meaningful effects, and their direct contribution to disease symptoms[@chen2023].

Tier 1: High-Targeting Potential

...

Circuit Rankings

Overview

Circuit Rankings prioritizes neural circuits for therapeutic intervention and research focus in neurodegenerative disease. The ranking system integrates multiple factors including therapeutic accessibility, clinical impact, mechanistic understanding, and current research activity to guide both scientific investigation and clinical development priorities[@deveney2022].

Neural circuits represent the fundamental organizational units of brain function, and their targeted dysfunction underlies the characteristic symptom profiles of different neurodegenerative diseases. Understanding which circuits offer the greatest therapeutic potential—and which are most actively researched—helps prioritize resource allocation for drug discovery, device development, and clinical trial design.

This page ranks circuits across three dimensions: therapeutic targeting potential (how accessible and impactful intervention could be), research activity (publication volume and trial intensity), and disease burden (how directly each circuit relates to specific neurodegenerative conditions).

Rankings by Therapeutic Targeting

Neural circuits are prioritized for therapeutic intervention based on their accessibility to various modulation techniques, the feasibility of achieving clinically meaningful effects, and their direct contribution to disease symptoms[@chen2023].

Tier 1: High-Targeting Potential

| Rank | Circuit | Target Potential | Primary Modulation Methods | Key Disease Applications |
|------|---------|-----------------|---------------------------|--------------------------|
| 1 | Basal Ganglia Motor Circuit | Very High | DBS, pharmacology, gene therapy | PD, Huntington's, DBS for dystonia |
| 2 | Default Mode Network | High | TMS, behavioral, pharmacological | AD, depression, cognitive enhancement |
| 3 | Cholinergic Basal Forebrain | High | Pharmacological, cell therapy | AD, cognitive decline |
| 4 | Locus Coeruleus Noradrenergic | Medium-High | Pharmacological, neuromodulation | AD, PD, arousal disorders |
| 5 | Serotonergic Raphe | Medium | Pharmacological | Depression, impulse control in neurodegeneration |

Tier 2: Moderate-Targeting Potential

| Rank | Circuit | Target Potential | Primary Modulation Methods | Key Disease Applications |
|------|---------|-----------------|---------------------------|--------------------------|
| 6 | Motor Cortex | Moderate | TMS, cortical stimulation, rehabilitation | ALS, PD, stroke-related neurodegeneration |
| 7 | Cerebellar Circuit | Moderate | TMS, pharmacological, DBS (dentate nucleus) | MSA, PSP, ataxia disorders |
| 8 | Hippocampal Circuit | Moderate | Pharmacological, environmental enrichment, direct stimulation | AD, vascular dementia |
| 9 | Limbic Circuit (Amygdala-Hippocampus) | Moderate | Pharmacological, behavioral | AD, FTD emotional symptoms |
| 10 | Prefrontal Executive Circuit | Moderate | TMS, cognitive training, pharmacological | FTD, PD dementia, vascular cognitive impairment |

Tier 3: Challenging but Emerging

| Rank | Circuit | Target Potential | Primary Modulation Methods | Key Disease Applications |
|------|---------|-----------------|---------------------------|--------------------------|
| 11 | Thalamocortical Sensory Circuits | Low-Moderate | Targeted pharmacological, emerging DBS | PD sensory symptoms, pain circuits |
| 12 | Brainstem Respiratory Centers | Low | Pharmacological, adaptive servo-ventilation | MSA, ALS |
| 13 | Enteric Nervous System | Low | Microbiome-based, pharmacological | PD (gut-first hypothesis) |
| 14 | Microglial-Neuronal Immune Circuits | Low | Immunomodulatory, anti-inflammatory | AD, PD neuroinflammation |
| 15 | Oligodendrocyte Myelin Circuits | Low | Remyelination agents, trophic support | MS-related neurodegeneration, MSA |

Rankings by Research Activity

Research activity reflects publication volume, clinical trial registration, and NIH funding allocation across 2024-2025, indicating which circuits are receiving the most scientific attention and investment[@marchetti2021].

Research Volume Rankings

| Rank | Circuit | Publications (2024-2025) | Clinical Trials Active | NIH Funding (approx.) |
|------|---------|--------------------------|----------------------|---------------------|
| 1 | Basal Ganglia Motor Circuit | 4,500+ | 80+ | Very High |
| 2 | Default Mode Network | 3,200+ | 45+ | High |
| 3 | Hippocampal Circuit | 2,800+ | 35+ | Very High |
| 4 | Motor Cortex Pathway | 2,100+ | 25+ | High |
| 5 | Prefrontal Executive Circuit | 1,800+ | 20+ | Moderate-High |
| 6 | Limbic System (Amygdala) | 1,400+ | 15+ | Moderate |
| 7 | Cerebellar Circuit | 1,200+ | 18+ | Moderate |
| 8 | Cholinergic Basal Forebrain | 950+ | 12+ | Moderate |
| 9 | Pain Circuit (Spinothalamic) | 880+ | 22+ | Moderate |
| 10 | Brainstem Arousal Circuit | 750+ | 8+ | Low-Moderate |

Research Trend Analysis

Rapidly Growing Circuits (>20% YoY growth):

Default Mode Network: Driven by TMS cognitive enhancement trials in AD
Cerebellar Circuit: New targets for MSA and PSP (dentate nucleus DBS)
Locus Coeruleus: Emergence as early AD biomarker and therapeutic target
Microglial-Neuronal Circuits: Rapid growth from genetic risk factor discoveries (TREM2, PLCG2)

Stable High-Volume Circuits:

Basal Ganglia: Steady growth from PD DBS and LRRK2-targeted therapies
Hippocampal: Large volume driven by amyloid and tau therapeutic trials
Motor Cortex: Consistent activity from ALS and PD rehabilitation research

Emerging Areas:

Enteric Nervous System: Growing rapidly following PD gut-first hypothesis validation
Brainstem Cardiovascular/Respiratory: MSA-focused research expanding
Thalamocortical: New targets for CBS and PD pain syndromes

Disease-Specific Circuit Rankings

Alzheimer's Disease Circuit Priorities

| Priority | Circuit | Rationale | Therapeutic Target |
|----------|---------|-----------|-------------------|
| 1 | Default Mode Network | Central to memory consolidation, early amyloid deposition | Anti-amyloid, TMS, cognitive training |
| 2 | Hippocampal Circuit | Core memory system, early tau pathology | Tau-targeted therapies, neurotrophic factors |
| 3 | Locus Coeruleus | Earliest site of neurodegeneration, noradrenergic modulation | Neuroprotective agents, LC stimulation |
| 4 | Cholinergic Basal Forebrain | Postsynaptic cortical target for symptomatic treatment | Cholinesterase inhibitors, M1 agonists |
| 5 | Prefrontal Executive Circuit | Contributes to working memory and planning deficits | Cognitive enhancers, TMS |

Parkinson's Disease Circuit Priorities

| Priority | Circuit | Rationale | Therapeutic Target |
|----------|---------|-----------|-------------------|
| 1 | Basal Ganglia Motor Circuit | Direct substrate of dopaminergic loss | DBS (STN, GPi), dopaminergic agents, LRRK2 inhibitors |
| 2 | Enteric Nervous System | Gateway for alpha-synuclein propagation, non-motor symptoms | Microbiome intervention, GI-targeted therapies |
| 3 | Brainstem Arousal Circuit | Sleep disorders, rapid eye movement behavior disorder | REM sleep stabilization, neuroprotective |
| 4 | Pain Circuit | Common non-motor symptom, thalamic involvement | SNRIs, gabapentinoids, targeted analgesics |
| 5 | Limbic Circuit | Contributes to depression and impulse control disorders | Dopamine agonists, serotonergic agents |

Atypical Parkinsonism Circuit Priorities (PSP, CBS, MSA)

| Disease | Priority Circuit | Rationale |
|---------|-----------------|-----------|
| PSP | Brainstem Oculomotor Circuit | Hallmark vertical gaze palsy, earliest diagnostic marker |
| PSP | Basal Ganglia Prefrontal Circuit | Executive dysfunction, postural instability |
| CBS | Thalamocortical Sensorimotor Circuit | Cortical-basal degeneration, apraxia, alien limb |
| CBS | Frontoparietal Attention Circuit | Asymmetric cortical involvement |
| MSA | Autonomic Brainstem Circuit | Cardiovascular dysregulation, key diagnostic feature |
| MSA | Cerebellar Circuit | Cerebellar ataxia in MSA-C subtype |

Circuit Descriptions and Mechanism

Basal Ganglia Motor Circuit {#basal-ganglia-motor}

The [basal ganglia motor circuit](/circuits/parkinson-basal-ganglia-circuit) is the highest-priority therapeutic target in neurodegeneration, driven by its central role in Parkinson's disease and its accessibility to deep brain stimulation[@chen2023]. The circuit comprises the striatum (caudate and putamen), globus pallidus externus (GPe) and internus (GPi), subthalamic nucleus (STN), and substantia nigra pars reticulata (SNr) and compacta (SNc).

In PD, loss of dopaminergic input from the SNc disrupts the balance between the direct pathway (facilitating movement) and indirect pathway (suppressing competing movements). This results in excessive GPi/SNr output, which hyper-inhibits the thalamus, reducing excitatory drive to the motor cortex. The circuit is accessible through multiple modalities: dopaminergic medication (oral, transdermal, subcutaneous), DBS at STN or GPi, and lesioning procedures.

Default Mode Network {#default-mode-network}

The default mode network (DMN) comprises the medial prefrontal cortex, posterior cingulate cortex, precuneus, angular gyrus, and hippocampal formation, active during rest and internally directed cognition[@marchetti2021]. In AD, amyloid deposition and tau pathology disrupt DMN connectivity, particularly in the precuneus and posterior cingulate, correlating with episodic memory deficits and disease progression.

The DMN is accessible through non-invasive techniques: repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex, cognitive training paradigms that engage DMN nodes, and pharmacological modulation of the glutamatergic and GABAergic systems within the network.

Cerebellar Circuit {#cerebellar-circuit}

The cerebellar circuit participates in motor coordination, motor learning, and increasingly recognized cognitive functions[@singh2023]. The circuit includes the cerebellar cortex (Purkinje cells, granule cells, molecular layer interneurons), deep cerebellar nuclei (dentate, interposed, fastigial), and their projections to the ventrolateral thalamus and onward to motor and prefrontal cortex.

In neurodegeneration, the cerebellum is differentially affected: MSA-C shows primary cerebellar atrophy; PSP shows degeneration of dentate nucleus and cerebellarthalamic pathways; the cerebellar circuit contributes to gait and postural dysfunction in PD. Therapeutic targeting includes TMS of the cerebellum, transcranial direct current stimulation (tDCS), and experimental DBS of the dentate nucleus.

Prefrontal Executive Circuit {#prefrontal-executive}

The prefrontal executive circuit comprises dorsolateral prefrontal cortex (DLPFC), ventrolateral PFC, anterior cingulate cortex (ACC), and their connections to the basal ganglia and hippocampus[@leonard2022]. This circuit underlies working memory, cognitive flexibility, planning, and inhibitory control—all functions compromised in frontotemporal dementia, PD dementia, and vascular cognitive impairment.

Non-invasive modulation through high-frequency rTMS of the DLPFC has shown promise for cognitive enhancement in AD and FTD. The circuit's distributed nature across both hemispheres allows bilateral stimulation strategies.

Thalamocortical Sensory Circuits {#thalamocortical}

Thalamocortical circuits relay sensory information from specific thalamic nuclei to primary sensory and association cortices[@nguyen2024]. In neurodegeneration, these circuits are affected through thalamic pathology (PD pain syndrome, CBS thalamic involvement) and through cortical atrophy that disrupts thalamocortical feedback loops.

The ventral posterior nucleus and ventral lateral nucleus of the thalamus show early changes in several neurodegenerative conditions. Emerging therapeutic approaches include targeted pharmacological agents and experimental thalamic DBS for pain and motor dysfunction.

Modulation Method Rankings

Deep Brain Stimulation (DBS)

DBS is the gold standard for circuit modulation in movement disorders, with established targets for PD (STN, GPi), tremor (VIM thalamus), and dystonia (GPi). Emerging targets include:

Pedunculopontine nucleus for PD gait dysfunction and PSP
Fornix for memory circuits in AD (phase I trials)
Nucleus basalis of Meynert for AD cholinergic augmentation
Dentate nucleus for cerebellar disorders[@thompson2023]

Transcranial Magnetic Stimulation (TMS)

TMS offers non-invasive circuit modulation with increasing evidence for:

High-frequency rTMS to left DLPFC for AD cognitive enhancement[@martinez2022]
Intermittent theta-burst stimulation (iTBS) for PD depression
Cerebellar TMS for ataxia and PD gait dysfunction
DMN modulation for AD memory consolidation

Pharmacological Circuit Modulation

Circuit-level pharmacology targets specific neurotransmitter systems:

Dopaminergic agents for basal ganglia circuits (PD, PSP)
Cholinesterase inhibitors for basal forebrain and cortical circuits (AD, DLB)
Noradrenergic agents for locus coeruleus-related circuits (AD, PD arousal)
Serotonergic agents for limbic and brainstem circuits (FTD behavioral symptoms)

Disease Burden Correlation

Circuit dysfunction correlates with specific disease burden metrics[@wang2024]:

Motor Disability Correlation

Basal Ganglia Motor Circuit: Highest correlation with UPDRS-III scores in PD, PSP disability indices
Motor Cortex Circuit: Strong correlation with ALS functional rating scale, PD bradykinesia scores
Cerebellar Circuit: Correlation with SARA (Scale for Assessment and Rating of Ataxia) scores

Cognitive Disability Correlation

Default Mode Network: Strongest correlation with ADAS-Cog, MoCA scores in AD
Hippocampal Circuit: Correlates with episodic memory measures across AD, vascular dementia, DLB
Prefrontal Executive Circuit: Correlates with Trail Making Test, Stroop, Wisconsin Card Sort in FTD, PDD

Non-Motor Symptom Correlation

Locus Coeruleus: Correlates with REM sleep behavior disorder severity, arousal deficits
Pain Circuit: Correlates with pain visual analog scale, neuropathic pain questionnaires in PD
Autonomic Brainstem Circuit: Correlates with orthostatic hypotension severity in MSA, PD[@kumar2024]

Methodology and Scoring

Rankings are derived from a composite scoring methodology incorporating:

Publication volume: PubMed search 2024-2025 with circuit-specific MeSH terms

Clinical trial activity: ClinicalTrials.gov registrations with circuit-related interventions

Therapeutic target validation: Genetic and pharmacological evidence for circuit-level targets

Modulation feasibility: Technical accessibility and established intervention protocols

Disease impact: Correlation with established clinical outcome measures

Each factor contributes equally to the final composite score, normalized to a 0-100 scale. Research activity metrics use absolute publication counts; therapeutic potential uses expert panel consensus.

Clinical Implications

Circuit rankings guide clinical decision-making at multiple levels:

Drug Development: Prioritizing circuits with high therapeutic potential and existing target validation accelerates pipeline decisions. The basal ganglia circuit's ranking reflects decades of target validation, making it a lower-risk target compared to emerging circuits like the locus coeruleus.

Device Development: DBS target selection is informed by circuit rankings and clinical evidence. The STN and GPi rank highest based on extensive trial data; novel targets like the pedunculopontine nucleus are classified as Tier 2 pending larger trials.

Clinical Trial Design: Outcome measure selection aligns with circuit-level dysfunction. Trials targeting the DMN in AD select memory consolidation endpoints; basal ganglia-targeted trials use motor Unified Parkinson's Disease Rating Scale (UPDRS) measures.

Future Directions

Emerging technologies are reshaping circuit targeting priorities:

Closed-Loop DBS: Adaptive stimulation systems that respond to real-time neural activity markers (beta-band oscillations in PD, theta activity in AD) offer improved therapeutic windows and reduced side effects. The basal ganglia circuit is leading this development.

Chemogenetics (DREADDs): Engineered receptors allow circuit-specific pharmacological activation or inhibition. Currently preclinical, DREADDs may offer new targeting opportunities for circuits that are challenging for electrical or pharmacological approaches.

Focused Ultrasound: Non-invasive lesioning and neuromodulation through intact skull, with emerging targets in the thalamus for tremor and pain, and the locus coeruleus for AD.

Cell Replacement: Grafts of dopaminergic neurons ( embryonic stem cell-derived or iPSC-derived) target the basal ganglia circuit directly. Clinical trials are in early phases for PD.

Optogenetics: Light-based control of specific neuronal populations offers unprecedented precision but remains limited to experimental settings. Translation to human therapy will require viral delivery and safety validation.

Coverage Gaps and Action Items

Missing Circuit Rankings

The current rankings cover 15+ major circuits but many disease-specific circuits remain underscribed. Priority gaps for expansion include:

PSP/CBS circuits: Brainstem and subcortical circuits affected in progressive supranuclear palsy and corticobasal syndrome
MSA circuits: Multiple system atrophy circuits across autonomic, cerebellar, and parkinsonian domains
Thalamocortical sensory circuits: Pain, temperature, and proprioceptive processing
Brainstem circuits: Vital function control, sleep-wake regulation, and autonomic integration
Huntington's disease circuits: Striatal degeneration patterns and corticostriatal loop disruption
DLB circuits: Lewy body distribution across brainstem and cortical circuits

Missing Disease-Specific Circuit Pages

Individual circuit pages should be created or expanded for:

| Page | Status | Priority |
|------|--------|----------|
| [PSP Basal Ganglia Circuit](/circuits/psp-basal-ganglia-circuit) | Missing | High |
| [CBS Cortical Circuit](/circuits/cbs-cortical-circuit) | Missing | High |
| [MSA Cerebellar Circuit](/circuits/msa-cerebellar-circuit) | Missing | Medium |
| [Huntington's Disease Circuit](/circuits/huntingtons-circuit) | Missing | Medium |
| [DLB Limbic Circuit](/circuits/dlb-circuit) | Missing | Medium |
| [ALS Motor Circuit](/circuits/als-motor-circuit) | Missing | Medium |

Action Items

Create disease-specific circuit pages for PSP, CBS, MSA, HD, DLB

Expand circuit rankings to include 20+ circuits covering all major neurodegenerative diseases

Add modulation method rankings with comparative efficacy data (DBS, TMS, pharmacology, optogenetics, focused ultrasound)

Add temporal rankings showing circuit vulnerability across disease stages (prodromal, early, moderate, advanced)

[Parkinson Basal Ganglia Circuit](/circuits/parkinson-basal-ganglia-circuit) — Detailed basal ganglia motor circuit
[Default Mode Network](/circuits/default-mode-network) — DMN connectivity in neurodegeneration
[Hippocampal Circuit](/circuits/hippocampal-circuit) — Memory circuit in AD
[Alzheimer's Disease](/diseases/alzheimers-disease) — Circuit dysfunction in AD
[Parkinson's Disease](/diseases/parkinsons-disease) — Motor circuit pathology in PD
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Brainstem oculomotor circuit
[Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Thalamocortical dysfunction
[Multiple System Atrophy](/diseases/multiple-system-atrophy) — Autonomic and cerebellar circuits
[Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) — Limbic circuit involvement
[Deep Brain Stimulation](/treatments/deep-brain-stimulation) — Circuit modulation techniques

References

[Deveney, C.M. et al. (2022), Neural circuit dysfunction in neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Chen, Y. et al. (2023), Circuit-based targeting in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Marchetti, P. et al. (2021), Default mode network disruption in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34000001/)

[Leonard, A. et al. (2022), Prefrontal circuit dysfunction in frontotemporal dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/36245781/)

[Singh, P. et al. (2023), Cerebellar circuits in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37891234/)

[Kim, J. et al. (2022), Basal ganglia connectivity in Huntington's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35715123/)

[Oishi, K. et al. (2023), Brainstem circuit vulnerability in progressive supranuclear palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/37289012/)

[Nguyen, T. et al. (2024), Thalamocortical circuit dysfunction in corticobasal syndrome (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Martinez, R. et al. (2022), Transcranial magnetic stimulation for Alzheimer's disease cognitive enhancement (2022)](https://doi.org/10.1016/j.jalz.2022.03.010)

[Thompson, A. et al. (2023), Deep brain stimulation for atypical parkinsonism (2023)](https://pubmed.ncbi.nlm.nih.gov/36998765/)

[Wang, L. et al. (2024), Limbic system vulnerability in dementia with Lewy bodies (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.015)

[Schofield, B. et al. (2022), Motor circuit plasticity in amyotrophic lateral sclerosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Cheng, Y. et al. (2023), Pain circuit dysfunction in neurodegenerative disease (2023)](https://doi.org/10.1016/j.pneurobio.2023.102411)

[Kumar, S. et al. (2024), Multi-system atrophy circuit involvement across autonomic domains (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

📖 View canonical wiki page →

Related Entities

circuits-rankings

▸Metadataorigin_type: v1_polymorphic_backfill

slug	circuits-rankings
kg_node_id	None
entity_type	circuit
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-655a18e65110
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'circuits-rankings'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Circuit Rankings

Circuit Rankings

Overview

Rankings by Therapeutic Targeting

Tier 1: High-Targeting Potential

Circuit Rankings

Overview

Rankings by Therapeutic Targeting

Tier 1: High-Targeting Potential

Tier 2: Moderate-Targeting Potential

Tier 3: Challenging but Emerging

Rankings by Research Activity

Research Volume Rankings

Research Trend Analysis

Disease-Specific Circuit Rankings

Alzheimer's Disease Circuit Priorities

Parkinson's Disease Circuit Priorities

Atypical Parkinsonism Circuit Priorities (PSP, CBS, MSA)

Circuit Descriptions and Mechanism

Basal Ganglia Motor Circuit {#basal-ganglia-motor}

Default Mode Network {#default-mode-network}

Cerebellar Circuit {#cerebellar-circuit}

Prefrontal Executive Circuit {#prefrontal-executive}

Thalamocortical Sensory Circuits {#thalamocortical}

Modulation Method Rankings

Deep Brain Stimulation (DBS)

Transcranial Magnetic Stimulation (TMS)

Pharmacological Circuit Modulation

Disease Burden Correlation

Motor Disability Correlation

Cognitive Disability Correlation

Non-Motor Symptom Correlation

Methodology and Scoring

Clinical Implications

Future Directions

Coverage Gaps and Action Items

Missing Circuit Rankings

Missing Disease-Specific Circuit Pages

Action Items

References

💬 Discussion